172 related articles for article (PubMed ID: 29887243)
1. Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301).
Atagi S; Mizusawa J; Ishikura S; Takahashi T; Okamoto H; Tanaka H; Goto K; Nakagawa K; Harada M; Takeda Y; Nogami N; Fujita Y; Kasai T; Kishi K; Sawa T; Takeda K; Tomii K; Satouchi M; Seto T; Ohe Y
Clin Lung Cancer; 2018 Sep; 19(5):e619-e627. PubMed ID: 29887243
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
Schild SE; Hillman SL; Tan AD; Ross HJ; McGinnis WL; Garces YA; Graham DL; Adjei AA; Jett JR;
J Thorac Oncol; 2017 Apr; 12(4):697-703. PubMed ID: 28089762
[TBL] [Abstract][Full Text] [Related]
3. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
[TBL] [Abstract][Full Text] [Related]
5. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
[TBL] [Abstract][Full Text] [Related]
6. Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer.
Johnson MD; Sura K; Mangona VS; Glick A; Wallace M; Ye H; Grills IS
Clin Lung Cancer; 2017 Mar; 18(2):149-155. PubMed ID: 27426973
[TBL] [Abstract][Full Text] [Related]
7. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
8. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
[TBL] [Abstract][Full Text] [Related]
9. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.
Casas F; Viñolas N; Ferrer F; Agustí C; Sanchez M; Maria Gimferrer J; Lomeña F; Campayo M; Jeremic B
J Thorac Oncol; 2011 Jan; 6(1):79-85. PubMed ID: 21150466
[TBL] [Abstract][Full Text] [Related]
11. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
Kozak MM; Murphy JD; Schipper ML; Donington JS; Zhou L; Whyte RI; Shrager JB; Hoang CD; Bazan J; Maxim PG; Graves EE; Diehn M; Hara WY; Quon A; Le QT; Wakelee HA; Loo BW
J Thorac Oncol; 2011 May; 6(5):920-6. PubMed ID: 21774104
[TBL] [Abstract][Full Text] [Related]
12. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
Phernambucq EC; Hartemink KJ; Smit EF; Paul MA; Postmus PE; Comans EF; Senan S
J Thorac Oncol; 2012 Aug; 7(8):1271-5. PubMed ID: 22659960
[TBL] [Abstract][Full Text] [Related]
13. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U
Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662
[TBL] [Abstract][Full Text] [Related]
14. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).
Atagi S; Kawahara M; Yokoyama A; Okamoto H; Yamamoto N; Ohe Y; Sawa T; Ishikura S; Shibata T; Fukuda H; Saijo N; Tamura T;
Lancet Oncol; 2012 Jul; 13(7):671-8. PubMed ID: 22622008
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
[TBL] [Abstract][Full Text] [Related]
16. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
17. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
Yao L; Xu S; Xu J; Yang C; Wang J; Sun D
Radiat Oncol; 2015 Jan; 10():10. PubMed ID: 25572571
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
[TBL] [Abstract][Full Text] [Related]
19. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract][Full Text] [Related]
20. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812).
Atagi S; Kawahara M; Tamura T; Noda K; Watanabe K; Yokoyama A; Sugiura T; Senba H; Ishikura S; Ikeda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2005 Apr; 35(4):195-201. PubMed ID: 15845568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
